Single-Agent Immunotherapy for Two Types of Cancer in One Patient

Letters5 February 2019Single-Agent Immunotherapy for Two Types of Cancer in One PatientBenjamin Musher, MD and Ahmad Rahal, MDBenjamin Musher, MDBaylor College of Medicine, Houston, Texas (B.M., A.R.)Search for more papers by this author and Ahmad Rahal, MDBaylor College of Medicine, Houston, Texas (B.M., A.R.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L18-0360 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer) is characterized by an inability to recognize and repair some errors that develop during DNA replication. This defect in mismatch repair is an autosomal dominant disorder that increases risk for several types of cancer, including colorectal, uterine, gastric, pancreatic, ovarian, and bile duct.Objective: To show that a single immunotherapeutic agent can successfully treat more than 1 type of cancer in the same patient when the cancer has a common genetic cause.Case Report: We evaluated a 55-year-old woman with extensive gastrointestinal cancer. The patient had a family history of ...References1. Lee V, Murphy A, Le DT, Diaz LA. Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist. 2016;21:1200-11. [PMID: 27412392] CrossrefMedlineGoogle Scholar2. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409-13. [PMID: 28596308] doi:10.1126/science.aan6733 CrossrefMedlineGoogle Scholar3. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273-81. [PMID: 20375404] doi:10.1056/NEJMoa0908721 CrossrefMedlineGoogle Scholar4. Bang YJ, Doi T, De Braud F, Piha-Paul S, Hollebecque A, Abdul Razak A, et al. Safety and efficacy of pembrolizumab (MK-3475) in patients with advanced biliary tract cancer: interim results of KEYNOTE-028. European Cancer Congress. 2015;51:S112. CrossrefMedlineGoogle Scholar5. Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36:1668-74. [PMID: 29283791] doi:10.1200/JCO.2017.75.6270 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Baylor College of Medicine, Houston, Texas (B.M., A.R.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L18-0360.This article was published at Annals.org on 25 September 2018. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byComplete Pathological Response to Neoadjuvant Chemoimmunotherapy in a Patient With Metastatic Intrahepatic Cholangiocarcinoma With High Tumor Mutational BurdenImmunology of Lynch SyndromeAn Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome 5 February 2019Volume 170, Issue 3Page: 210-211KeywordsCancer immunotherapyCancer treatmentCellsColonColorectal cancerHereditary nonpolyposis colorectal cancerLiverMismatch repairTomographyUterine cancer ePublished: 25 September 2018 Issue Published: 5 February 2019 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...